Research Portal

Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Standard Standard

Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. / Pijeira Perez, Yankier; Hughes, Dyfrig.
OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Vol. 40 Special Issue S1. ed. International Journal of Technology Assessment in Health Care., 2025.

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

HarvardHarvard

Pijeira Perez, Y & Hughes, D 2025, Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. in OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Special Issue S1 edn, vol. 40, International Journal of Technology Assessment in Health Care., Health Technology Assessment International (HTAi) 2024 Meeting, Seville, Spain, 15/06/24. https://doi.org/10.1017/S026646232400103X

APA

Pijeira Perez, Y., & Hughes, D. (2025). Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. In OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain (Special Issue S1 ed., Vol. 40). International Journal of Technology Assessment in Health Care.. https://doi.org/10.1017/S026646232400103X

CBE

Pijeira Perez Y, Hughes D. 2025. Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. In OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Special Issue S1 ed. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/S026646232400103X

MLA

Pijeira Perez, Yankier and Dyfrig Hughes "Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis". OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Special Issue S1 udg., International Journal of Technology Assessment in Health Care. 2025. https://doi.org/10.1017/S026646232400103X

VancouverVancouver

Pijeira Perez Y, Hughes D. Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. In OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Special Issue S1 ed. Vol. 40. International Journal of Technology Assessment in Health Care. 2025 doi: 10.1017/S026646232400103X

Author

Pijeira Perez, Yankier ; Hughes, Dyfrig. / Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis. OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.: Abstracts from the HTAi 2024 Meeting in Seville, Spain . Vol. 40 Special Issue S1. ed. International Journal of Technology Assessment in Health Care., 2025.

RIS

TY - GEN

T1 - Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis

AU - Pijeira Perez, Yankier

AU - Hughes, Dyfrig

PY - 2025/1/7

Y1 - 2025/1/7

N2 - There are concerns with the National Institute for Health and Care Excellence (NICE) conditional approval process with respect to the quality and reliability of the methods of evidence generation, analysis, and reporting; and on the increasing focus on OwR (only with research) in preference to OiR (only in research). Our study critically appraises the methods, quality, and risk of bias of the evidence generated in response to NICE conditionally approved technologies.

AB - There are concerns with the National Institute for Health and Care Excellence (NICE) conditional approval process with respect to the quality and reliability of the methods of evidence generation, analysis, and reporting; and on the increasing focus on OwR (only with research) in preference to OiR (only in research). Our study critically appraises the methods, quality, and risk of bias of the evidence generated in response to NICE conditionally approved technologies.

U2 - 10.1017/S026646232400103X

DO - 10.1017/S026646232400103X

M3 - Conference contribution

VL - 40

BT - OP41 Pharmaceutical Technologies Conditionally Approved By The National Institute For Health And Care Excellence: A Critical Analysis.

PB - International Journal of Technology Assessment in Health Care.

T2 - Health Technology Assessment International (HTAi) 2024 Meeting

Y2 - 15 June 2024 through 19 June 2024

ER -